2 / 6
Volume 7
OMICS Journal of Radiology
Radiology and Oncology 2018
July 16-17, 2018
Page 24
conference
series
.com
July 16-17, 2018 Dubai, UAE
Radiology and Oncology
2
nd
World Congress on
Radioprotective effects of the anti-cancer preparation NSC 631570 (Ukraine)
W
hen NSC 631570 has been used in clinic, it was observed that the patients treated with this drug tolerate the
concomitant radiotherapy much better. The adverse effects of this aggressive treatment modality were significantly
reduced to minimal. This gave reason to study radioprotective properties of NSC 631570 in the
in vitro
and
in vivo
tests. The
radioprotective effect of NSC 631570 has been confirmed by the infection models in mice where its effect was superior to
the effect of the known radioprotector Cysteamine. Compared to other agents, NSC 631570 exerted a strong radioprotective
effect similar to such of lymphokinin. These radioprotective properties of NSC 631570 were confirmed in further studies in
rats at the Institute of Applied Cell Culture (Munich, Germany). Ukrain normalized the level of nuclear thyroid hormone
receptors influenced by short-term, whole body gamma-irradiation of rats with 1 Gy, beginning from the first day after
administration of the drug. Thus, authors concluded Ukrain can minimize the consequences of irradiation on the endocrine
system of experimental animals. The radio protective effect of NSC 631570 was also studied and confirmed on in vitro
models on the human skin firbroblasts HSF1 and HSF2 as well as lung fibroblasts CCD32-LU. Differential effects of NSC
631570 in modulating radiation toxicity of human cancer cell lines and its protective effect in normal human fibroblasts
suggest that this agent may be beneficial for clinical radiochemotherapy.
Biography
Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He has completed his study at the
Radiotechnical Faculty of the Technical, University of Lviv, Ukraine. He is the author of over 300 scientific articles dedicated to cancer research. He is a member
of the New York Academy of Sciences, member of the European Union for Applied Immunology and American Association for Scientific Progress, Doctor “Honoris
causa” of the Open International University on Complex Medicine in Colombo, Honorary member of the Austrian Society Albert Schweizer. He has received the
award for merits of National Guild of Pharmasists of America, the award of Austrian Society of Sanitary, Hygiene and Public Health Services and others.
dr.nowicky@yahoo.deWassil Nowicky
Ukrainian Anti-Cancer Institute, Austria
Wassil Nowicky, OMICS J Radiol 2018, Volume 7
DOI: 10.4172/2167-7964-C1-020